| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |